JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
Unusual Causes of Headache
Neurol 48:1494-1499, Ramadan,N.M., 1997
Relapsing and Remitting Human Immunodeficiency Virus-Associated Leukoencephalomyelopathy
Ann Neurol 31:34-38, Berger,J.R.,et al, 1992
Multiple Sclerosis-Like Illness Occurring with Human Immunodeficiency Virus Infection
Neurol 39:324-329, Berger,J.R.,et al, 1989
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Relapsing-Remitting Multiple Sclerosis and Human Herpesvirus 6 Active Infection
Arch Neurol 61:1523-1527, Alvarez-Lafuente,R.,et al, 2004
Herpes Simplex Virus in Postmortem Multiple Sclerosis Brain Tissue
Arch Neurol 53:125-133, 1231996., Sanders,V.J.,et al, 1996
Subacute Leukoencephalitis Caused by CNS Infection with Human Herpesvirus-6 Manifesting as Acute Multiple Sclerosis
Neurol 47:145-148, Carrigan,D.R.,et al, 1996
Multiple Sclerosis, Retroviruses, and PCR
Neurol 41:335-343, Ehrlich,G.D.,et al, 1991
Retroviruses and Multiple Sclerosis. I. Analysis of Seroreactivity by Western Blot and Radioimmune Assay
Neurol 40:1251-1253, Weinshenker,B.G.,et al, 1990
Retroviruses & Multiple Sclerosis. II. Failure of Gene Amplification Techniques to Detect Viral Sequences
Neurol 40:1254-1258, Dekaban,G.A.&Rice,G.P.A., 1990
Multiple Sclerosis or HTLV-I Myelitis
Neurol 40:1020-1022, Poser,C.M.,et al, 1990
HTLV-I Sequences Are Not Detected in Peripheral Blood Genomic DNA or in Brain cDNA of MS Patients
Ann Neurol 28:574-577, Oksenberg,J.R.,et al, 1990
Failure to Detect Human T-Cell Leukemia Virus-Related Sequences in Multiple Sclerosis Blood
Arch Neurol 47:1064-1065, Chen,I.S.Y.,et al, 1990
No Evidence for Human T-Cell Leukemia Virus Type I or Human T-Cell Leukemia Virus Type II Infection in Patients with MS
Arch Neurol 47:1061-1063, Perl,A.,et al, 1990
HTLV-I-Associated Myelopathy:Oligoclonal Immunoglobulin G Bands Contain Anti-HTLV-I-p24 Antibody
Ann Neurol 24:727-731, Grimaldi,L.M.E.,et al, 1988
Antibody to Human T-Lymphotropic Virus Type I In West-Indian-Born UK Residents with Spastic Paraparesis
Lancet 1:415-416, Newton,M.,et al, 1987
Retrovirus-Associated Myelopathies
Arch Neurol 44:659-663, Roman,G.C., 1987
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Clinical and Neuroradiologic Features of Acute Disseminated Encephalomyelitis in Children
Neurol 56:1308-1312,1257, Hynson,J.L.,et al, 2001
Multiple Sclerosis
NEJM 343:938-952, Noseworthy,J.H. et al, 2000
Diffusion-Weighted MR Imaging of the Brain
Radiology 217:331-345, Schaefer,P.W.,et al, 2000
Cerebrospinal Fluid
JNNP 59:349-357, Thompson,E.J., 1995
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994